Pulmonary artery involvement contributes to the recurrence of hemoptysis after bronchial artery embolization in patients with chronic pulmonary aspergillosis Authors: Yingjie Chen, Min Liu, Wei Yu, Jinnan Zhong, Shi Chen, Ting Zhang, Wei Qin, Ziyang Zhu, Chenghong Li, Fajiu Li Published: 2026 ABSTRACT AbstractBackgroundPatients with chronic pulmonary aspergillosis (CPA) frequently face severe clinical challenges due to hemoptysis. Although bronchial artery embolization (BAE) is effective in controlling acute hemoptysis, the long-term recurrence rate remains high (up to 50%). Current research has mostly focused on culprit vessels originating from the systemic circulation, whereas the role of the pulmonary artery system (e.g., pulmonary artery pseudoaneurysm) in hemoptysis recurrence remains unclear. This study aimed to analyze the clinical characteristics of patients with CPA complicated by hemoptysis who underwent BAE, and to identify independent risk factors for hemoptysis recurrence.MethodsIn this single-center retrospective observational study, 58 CPA patients who underwent BAE for hemoptysis between January 2021 and January 2024 were enrolled. Based on hemoptysis recurrence within one-year post-procedure, patients were divided into a recurrence group (n=23) and a non-recurrence group (n=29). Baseline characteristics, imaging findings, and details of interventional procedures were collected. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors for hemoptysis recurrence, and Kaplan-Meier survival curves were plotted.ResultsAmong the 58 patients, the median age was 63 years and 62.1% were male. The one-year recurrence rate was 39.7%. Univariate analysis revealed that male sex, parenchymal destruction, the presence of three or more underlying pulmonary diseases, pulmonary artery involvement, and an increased number of embolized non-bronchial systemic arteries were associated with recurrence (P<0.05). Multivariate Cox regression analysis indicated that pulmonary artery involvement was an independent risk factor for hemoptysis recurrence after BAE [hazard ratio (HR) =3.43, 95% confidence interval (CI): 1.31–9.02, P=0.01]. The proportion of patients with pulmonary artery involvement was significantly higher in the recurrence group than in the non-recurrence group (60.9% vs. 27.6%, P=0.02). Hemoptysis-free survival was significantly shorter in patients with pulmonary artery involvement (P=0.008).ConclusionsPulmonary artery involvement is an important independent risk factor for hemoptysis recurrence after BAE in patients with CPA. This finding suggests that the pathological mechanism of hemoptysis in CPA involves “a dual systemic-pulmonary circulation mechanism”. In clinical practice, when performing interventional therapy for CPA patients with hemoptysis, in addition to the thorough embolization of culprit systemic arteries, routine assessment and active management of pulmonary artery lesions should be considered, as this may help reduce the long-term risk of recurrence.Keywords: Chronic pulmonary aspergillosis (CPA), hemoptysis, bronchial artery embolization (BAE), recurrence, pulmonary artery pseudoaneurysm (PAP) Highlight box Key findings • Pulmonary artery involvement (e.g., pseudoaneurysm) is an independent risk factor for hemoptysis recurrence after bronchial artery embolization (BAE) in chronic pulmonary aspergillosis (CPA) patients. Patients with pulmonary artery involvement had significantly higher recurrence rates and shorter hemoptysis-free survival. What is known and what is new? • It is known that BAE is effective for immediate hemoptysis control in CPA, but recurrence remains high. Prior research focused on systemic circulation sources (bronchial and non‑bronchial arteries). • This study newly highlights the role of pulmonary artery lesions in recurrence and proposes a “dual systemic‑pulmonary circulation” mechanism in CPA‑related hemoptysis. What is the implication, and what should change now? • The findings suggest that CPA‑related hemoptysis management should evolve from systemic‑only embolization to a dual circulation assessment. Clinicians should routinely evaluate and consider embolization of pulmonary artery lesions alongside systemic arteries to reduce long‑term recurrence risk. Introduction Chronic pulmonary aspergillosis (CPA) is a slowly progressive pulmonary infection caused by Aspergillus species. It typically occurs in individuals with pre-existing structural lung diseases [such as chronic obstructive pulmonary disease (COPD), bronchiectasis, mycobacterium tuberculosis or non-tuberculous mycobacterial infections] or impaired immune function (1,2). Its clinical manifestations are diverse, with hemoptysis being one of the most common and critical complications. Approximately 50% of CPA patients experience hemoptysis during their disease course, ranging from blood-streaked sputum to life-threatening massive hemoptysis (3). The pathological basis of hemoptysis in CPA is complex, primarily related to the invasion of lung tissue and adjacent blood vessels by Aspergillus. The fungus colonizes pulmonary cavities to form aspergillomas. The secreted toxins and proteases from these aspergillomas can erode vascular walls, triggering local inflammation, neovascularization, and abnormal vascular communications (4). The responsible vessels include not only hypertrophied and tortuous bronchial arteries but also ectopic bronchial arteries and non-bronchial systemic arteries (NBSAs), collectively forming a rich collateral blood supply from the systemic circulation (5,6). Based on this pathological mechanism, Bronchial Artery Embolization (BAE), due to its minimally invasive and highly effective nature, has become the first-line interventional treatment for controlling CPA-related hemoptysis, especially acute massive hemoptysis. Its immediate hemostasis success rate can reach 64–100%. However, the medium- to long-term efficacy of BAE in CPA patients is suboptimal, with recurrence rates reaching up to 50% of patients (3). Recent studies suggest that invasively growing Aspergillus may similarly erode the pulmonary circulation system, leading to the formation of pulmonary artery pseudoaneurysms (PAPs) (7). Furthermore, the fundamental role of antifungal therapy, the value of local airway interventions, and the influence of systemic hemodynamic factors on recurrence all play significant roles in the comprehensive management of CPA-related hemoptysis, yet related clinical evidence remains scarce. Therefore, an in-depth investigation into the clinical characteristics and outcomes of CPA patients with hemoptysis treated with BAE, and the identification of risk factors for recurrent hemoptysis, are crucial for optimizing treatment strategies and improving patient prognosis. This study aims to retrospectively analyze the clinical data of CPA patients with hemoptysis who underwent BAE treatment at a single center, to explore the factors associated with hemoptysis recurrence. We present this article in accordance with the STROBE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1-2725/rc). Methods Study design This single-center retrospective observational analysis included all patients diagnosed with CPA in the Department of Pulmonary and Critical Care Medicine at The Affiliated Hospital of Jianghan University between January 2021 and January 2024. This study was approved by the Ethics Committee of The Affiliated Hospital of Jianghan University (approval No. WHSHIRB-G-2024002). All participants provided written informed consents prior to the study. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Based on the inclusion criteria, eligible individuals were aged ≥18 years, diagnosed with CPA according to the 2016 guidelines from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Respiratory Society (ERS) (4). Among these, 58 patients who underwent BAE for hemoptysis were enrolled. Patients were followed up for one year after discharge and were categorized into a recurrence group and a non-recurrence group based on the presence or absence of hemoptysis recurrence (see Figure 1). The flowchart of selecting the study population. BAE, bronchial artery embolization; NTM, nontuberculous mycobacteria. Pulmonary artery involvement was defined as PAP confirmed by pulmonary angiography, characterized by persistent extravasation of contrast agent from the rupture site of the pulmonary artery into the aneurysmal cavity, forming a saccular or pouch-like opacity communicating with the arterial lumen (7) (see Figure 2, Videos 1,2). Pulmonary artery pseudoaneurysm depicted on CT pulmonary angiography and pulmonary angiography (arrows). Mediastinal window, MIP images, and three-dimensional reconstruction all show a pulmonary artery pseudoaneurysm (A-C). Pulmonary angiography demonstrates opacification of the pulmonary artery pseudoaneurysm (D). CT, computed tomography. Pulmonary angiography shows visualization of a pulmonary artery pseudoaneurysm. Repeat angiography after coil embolization showed disappearance of the pulmonary artery pseudoaneurysm. Recurrent hemoptysis was defined as the expectoration of blood alone without mucus from the airways or lung parenchyma after BAE (8), requiring medical intervention (i.e., prompting a clinic visit, emergency department evaluation, or hospitalization) or re-intervention (e.g., repeat BAE or surgery). Patients were followed up for one year after discharge. During the follow-up, the researchers determined the status of patients including recurrence, time to recurrence, treatment details and survival status by telephone contact or outpatient visits every month. BAE procedure All angiographic and embolization procedures were performed by experienced interventional pulmonologists. Prior to BAE, all patients underwent bronchial artery computed tomography angiography (CTA) to localize the site of bleeding and assess the suspected bleeding vessels. With the patient in the supine position and connected to cardiac monitoring for vital signs, vascular access was obtained under ultrasound guidance using a micropuncture kit. Access was via the femoral artery (for systemic arterial approach) or femoral vein (for pulmonary arterial approach) using the Seldinger technique, typically with a 4–6 F introducer sheath. Bronchial and non-bronchial systemic artery embolization: a contrast guidewire was used to guide a diagnostic catheter into the aorta. Based on pre-procedural CTA findings, the catheter was positioned near the suspected origin of the target responsible vessel. Selective catheterization was performed, and iodinated contrast was injected to confirm the vessel. Further angiography was performed to clarify the vessel diameter, course, branches, and distal vascular bed. Responsible vessels were identified based on: (I) direct signs: extravasation of contrast medium; (II) indirect signs: (i) abnormal hypertrophy and tortuosity of the bronchial artery; (ii) disorganized hyperplasia of the distal vascular bed; (iii) systemic-to-pulmonary circulation shunts; (iv) PAP. A microcatheter (potentially with microguidewire assistance) was then advanced into the mid-to-distal segment of the responsible vessel, avoiding non-target branches. After confirming the absence of contrast reflux, appropriate embolic agents were selected based on the vessel characteristics. Typically, 250–500 µm polyvinyl alcohol particles (Contour; Boston Scientific, Massachusetts, USA) and 560–1,000 µm gelatin sponge particles (EGgel S plus, Engain, Gangwon-do, South Korea) were used for embolization. Pulmonary artery embolization: a 5-F angiographic catheter (Davis catheter; Cook, Indiana, USA) was used to perform segmental or subsegmental pulmonary artery angiography to identify the feeding branch of a PAP. After identifying the feeding branch and the PAP, embolization was performed by co-axially delivering 3-6 mm microcoils (Tornado®, Nester®; Cook) through a 1.7-F or 2.0-F microcatheter (Progreat; Terumo, Tokyo, Japan; or Veloute; Asahi Intecc, Aichi, Japan). Post-embolization angiography was performed to confirm the immediate technical success. Upon completion, the catheters and sheaths were removed. The puncture site was locally compressed and bandaged. For patients with femoral arterial access, limb immobilization was maintained for 12–18 hours. Statistical analysis Statistical analysis was performed using IBM SPSS Statistics version 22. Data visualization was conducted using GraphPad Prism 8 software. Continuous variables are presented as mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables are described as frequency (%). Differences between groups were analyzed using the Mann-Whitney U test, χ2 test, or Fisher’s exact test, as applicable. Potential influencing factors were screened using univariate Cox regression models. Variables showing statistical significance in univariate analysis were further assessed for their prognostic value using a multivariate Cox proportional hazards model, with results expressed as hazard ratio (HR) with corresponding 95% confidence interval (CI). Kaplan-Meier curves were plotted using R software (version 4.2.2) to assess patient hemoptysis-free survival, and differences between groups were compared using the log-rank test. A P value <0.05 was considered statistically significant. Results CPA Patients with hemoptysis treated with BAE A total of 58 patients with CPA who underwent BAE for recurrent or massive hemoptysis were included in this study. Their baseline characteristics are summarized in Table 1. The median age was 63.0 years, and 36 patients (62.1%) were male. Eighteen patients (31.0%) had a body mass index (BMI) below 18.5 kg/m2, and 13 (22.4%) had a history of smoking. Thirty-one patients (53.4%) had previously received prior triazole antifungal therapy for pulmonary aspergillosis. Massive hemoptysis was present in 30 patients (51.7%), among whom 5 (8.6%) required endotracheal intubation. Aspergillus was detected in bronchoalveolar lavage fluid during hospitalization in 53 patients (91.4%). Past medical history included pulmonary tuberculosis in 36 patients (62.1%), COPD in 12 (21.1%), history of lung resection in 4 (6.9%), and parenchymal destruction in 19 (32.8%). Comorbidities included hypertension in 22 patients (38.6%) and diabetes mellitus in 6 (10.5%). Chest computed tomography (CT) scans revealed pulmonary cavities in 41 patients (70.7%), with an air crescent sign observed in 12 (19.0%) and nodular opacities in 27 (46.6%). Digital subtraction angiography (DSA) identified involvement of the following artery types: bronchial arteries in 54 patients (93.1%), ectopic bronchial arteries in 39 (67.2%), NBSAs in 56 (96.6%), and pulmonary arteries in 23 (39.7%). Table 1Baseline characteristics of CPA patients with hemoptysisDemographicsTotal cases (n=58)Age (years)63.00 [57.00, 67.00]Male36 (62.1)Body mass index <18.5 kg/m218 (31.0)Smoking history13 (22.4)Antifungal treatment ever before BAE31 (53.4)Massive hemoptysis30 (51.7)Endotracheal intubation5 (8.6)Detection of aspergillus in BALF53 (91.4)Underlying lung disease History of tuberculosis36 (62.1) COPD12 (21.1) History of lung surgery4(6.9) Parenchymal destruction19 (32.8)Comorbidities Hypertension22 (38.6) Diabetes6 (10.5)Laboratory indicators hs-CRP (mg/L)5.75 [1.71, 34.57] ESR (mm/h)27.00 [17.50, 59.00] Leukocyte (109/L)6.23 [5.42, 8.24] Lymphocyte (109/L)1.06 [0.85, 1.44] Hb (g/L)118.12±19.06 PLT (109/L)193.00 [172.00, 256.00] D-dimer (mg/L)0.52 [0.36, 1.35]Imaging Air crescent sign12 (19.0) Pulmonary cavity41 (70.7) Nodular opacity27 (46.6)Types of arteries embolized under DSA Bronchial artery54 (93.1) Ectopic bronchial artery39 (67.2) Non-bronchial systemic artery56 (96.6) Pulmonary artery23 (39.7)Data are presented as median [interquartile range], n (%), or mean ± standard deviation. BA, bronchial artery; BAE, bronchial artery embolization; BALF, bronchoalveolar lavage fluid; COPD, chronic obstructive pulmonary disease; CPA, chronic pulmonary aspergillosis; DSA, digital subtraction angiography; EBA, ectopic bronchial artery; ESR, erythrocyte sedimentation rate; Hb, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; NBSA, non-bronchial systemic artery; PLT, platelet. Baseline characteristics of CPA patients with hemoptysis Data are presented as median [interquartile range], n (%), or mean ± standard deviation. BA, bronchial artery; BAE, bronchial artery embolization; BALF, bronchoalveolar lavage fluid; COPD, chronic obstructive pulmonary disease; CPA, chronic pulmonary aspergillosis; DSA, digital subtraction angiography; EBA, ectopic bronchial artery; ESR, erythrocyte sedimentation rate; Hb, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; NBSA, non-bronchial systemic artery; PLT, platelet. Comparison of clinical characteristics between recurrence and no-recurrence groups Among the 58 CPA patients treated with BAE, one patient died due to recurrent massive hemoptysis after BAE, three patients died during the one-year follow-up period, and two were lost to follow-up. Hemoptysis recurred within one year in 23 patients. Table 2 compares the clinical characteristics between patients with and without hemoptysis recurrence. No significant differences were observed between the two groups in age, BMI, or smoking history. However, the recurrence rate after BAE was significantly higher in male patients (P=0.03). Among coexisting pulmonary diseases, there were no significant differences in the history of pulmonary tuberculosis, COPD, or history lung resection. However, patients with parenchymal destruction had a significantly higher recurrence rate (P=0.047). Additionally, patients with three or more underlying pulmonary diseases had a significantly higher recurrence rate (P=0.03). There were no significant differences between the groups in the number of involved lung lobes, receipt of prolonged antifungal therapy (>6 months), inflammatory markers (high-sensitivity C-reactive protein, erythrocyte sedimentation rate, white blood cell count), lymphocyte count, hemoglobin level, platelet count, or D-dimer level. Table 2Comparison of clinical characteristics between non-recurrence and recurrence groupsDemographicsNo-recurrence (n=29)Recurrence (n=23)PAge (years)65.00 [60.00, 70.00]60.00 [56.00, 66.00]0.10Male13 (44.8)18 (78.3)0.03Body mass index <18.5 kg/m28 (27.6)7 (30.4)>0.99Smoking history5 (17.2)8 (34.8)0.26Underlying lung disease History of tuberculosis19 (65.5)16 (69.6)>0.99 COPD3 (10.3)5 (21.7)0.46 History of lung surgery1 (3.4)3 (13.0)0.44 Parenchymal destruction7 (24.1)12 (52.2)0.047≥3 underlying lung diseases5 (17.2)11 (47.8)0.03Involved lobes of the lung3.00 [2.00, 4.00]3.00 [2.50, 4.00]0.49Duration of antifungal treatment after BAE6.00 [3.00, 12.00]6.00 [3.00, 12.00]0.91Antifungal treatment over 6 months after BAE10 (34.5)8 (34.7)>0.99Laboratory indicators hs-CRP (mg/L)3.95 [1.49, 10.33]6.72 [1.74, 24.19]0.50 ESR (mm/h)20.00 [9.00, 35.50]30.50 [20.00, 42.50]0.12 Leukocyte (109/L)6.14 [5.50, 7.43]6.04 [5.39, 7.76]0.87 Lymphocyte (109/L)1.05 [0.87, 1.30]1.07 [0.76, 1.56]0.99 Hb (g/L)115.83±19.59121.57±20.280.31 PLT (109/L)193.00 [172.00, 245.00]197.00 [177.50, 268.50]0.44 D-dimer (mg/L)0.63 [0.35, 1.00]0.42 [0.35, 1.35]0.50Types of arteries under DSA BA29 (100.0)19 (82.6)0.07 EBA22 (75.9)12 (52.2)0.14 NBSA28 (96.6)22 (95.7)>0.99 Pulmonary artery8 (27.6)14 (60.9)0.02Number of arteries embolized at BAE Number of BA2.00 [1.00, 2.00]2.00 [1.00, 2.00]0.96 Number of EBA1.00 [1.00, 1.00]0.00 [0.00, 1.00]0.26 Number of NBSA4.00 [3.00, 8.00]9.00 [4.50, 10.50]0.03Data are presented as median [interquartile range], n (%), or mean ± standard deviation. BA, bronchial artery; BAE, bronchial artery embolization; COPD, chronic obstructive pulmonary disease; DSA, digital subtraction angiography; EBA, ectopic bronchial artery; ESR, erythrocyte sedimentation rate; Hb, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; NBSA, non-bronchial systemic artery; PLT, platelet. Comparison of clinical characteristics between non-recurrence and recurrence groups Data are presented as median [interquartile range], n (%), or mean ± standard deviation. BA, bronchial artery; BAE, bronchial artery embolization; COPD, chronic obstructive pulmonary disease; DSA, digital subtraction angiography; EBA, ectopic bronchial artery; ESR, erythrocyte sedimentation rate; Hb, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; NBSA, non-bronchial systemic artery; PLT, platelet. Angiographic findings showed no significant differences between the two groups in the involvement of bleeding-related bronchial arteries, ectopic bronchial arteries, or NBSAs. However, pulmonary artery involvement was significantly more frequent in the recurrence group (P=0.02), manifesting as pulmonary artery aneurysm or pseudoaneurysm. The number of embolized bronchial arteries and ectopic bronchial arteries during BAE did not differ significantly between groups. In contrast, the median number of embolized NBSAs was significantly higher in the recurrence group (9 arteries) than in the no-recurrence group (4 arteries) (P=0.03). Cox regression analysis of risk factors for hemoptysis recurrence As shown in Table 3, univariate Cox regression analysis indicated that male sex, parenchymal destruction, the number of embolized NBSAs, having more than three underlying pulmonary diseases, and the involvement of bronchial or pulmonary arteries were associated with hemoptysis recurrence. On multivariate Cox regression analysis, only pulmonary artery involvement remained an independent risk factor for recurrence (HR, 3.43; 95% CI: 1.31–9.02; P=0.01). Table 3Univariate and multivariate Cox regression analyses of factors associated with hemoptysis recurrence in patients with chronic pulmonary aspergillosisCharacteristicsUnivariate analysisMultivariate analysisHR95% CIP valueHR95% CIP valueAge (years)0.970.94–1.010.100.960.92–1.000.08Sex2.911.08–7.870.041.850.64–5.360.26Body mass index <18.5 kg/m21.190.49–2.900.70Underlying lung disease History of tuberculosis1.110.46–2.690.82––– COPD1.790.66–4.820.25––– History of lung surgery2.820.83–9.530.10––– Parenchymal destruction2.611.15–5.930.020.950.30–3.040.93 ≥3 underlying lung diseases3.021.33–6.870.0092.360.78–7.150.13Antifungal treatment over 6 months after BAE0.860.37–2.040.740.460.17–1.230.12Types of arteries under DSA BA0.220.07–0.670.008––– EBA0.480.21–1.090.08––– NBSA0.910.12–6.760.93––– Pulmonary artery2.951.27–6.850.013.701.41–9.730.008Number of arteries embolized at BAE Number of BA0.810.47–1.40.46––– Number of EBA1.020.58–1.800.93––– Number of NBSA1.081.01–1.160.021.060.97–1.160.20BA, bronchial artery; BAE, bronchial artery embolization; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DSA, digital subtraction angiography; EBA, ectopic bronchial artery; HR, hazard ratio; NBSA, non-bronchial systemic artery. Univariate and multivariate Cox regression analyses of factors associated with hemoptysis recurrence in patients with chronic pulmonary aspergillosis BA, bronchial artery; BAE, bronchial artery embolization; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DSA, digital subtraction angiography; EBA, ectopic bronchial artery; HR, hazard ratio; NBSA, non-bronchial systemic artery. Kaplan-Meier survival analysis Figure 3 shows the Kaplan-Meier curve for hemoptysis-free survival in the 52 patients. Figure 4 demonstrates that patients with pulmonary artery involvement had a significantly shorter hemoptysis-free survival period compared to those without pulmonary artery involvement (P=0.008). Kaplan-Meier analysis of hemoptysis-free survival. Kaplan-Meier estimates of hemoptysis-free survival in patients with and without pulmonary artery involvement. Discussion Patients with CPA often face significant clinical challenges due to recurrent hemoptysis, garnering considerable attention. Existing research indicates that while BAE achieves a high short-term success rate in controlling hemoptysis, its long-term efficacy remains suboptimal. For instance, studies report re-bleeding rates as high as 52% within a median of 2 months for patients with simple aspergilloma or CPA (6). Currently, research on factors influencing recurrent hemoptysis in CPA patients is insufficient. Therefore, this study aimed to analyze the clinical characteristics of such patients and explore factors associated with hemoptysis recurrence, aiming to provide a basis for improving clinical outcomes. This retrospective analysis of 58 CPA patients who underwent BAE for hemoptysis found a recurrence rate of 39.7% within a one-year follow-up period. Multivariate Cox regression analysis further revealed that pulmonary artery involvement is an independent risk factor for hemoptysis recurrence after BAE in CPA patients. This finding suggests that, for this specific population, the responsible vasculature for hemoptysis has a dual nature. Consequently, interventional treatment strategies should evolve from the traditional, singular focus on “systemic circulation embolization” to a comprehensive “dual systemic-pulmonary circulation evaluation” model. In China, the prevalence of tuberculosis is higher among males, and the smoking rate is significantly higher among males than among females (9). This may explain the findings of this study: a higher proportion of males and a greater history of smoking among males in the CPA cohort. Furthermore, the presence of a parenchymal destruction was associated with hemoptysis recurrence after BAE in CPA patients, consistent with previous findings by Wang et al. (10). Therefore, patients with chronic infectious diseases accompanied by parenchymal destruction represent a high-risk group for hemoptysis recurrence and should be considered as key targets for close follow-up. Previous studies widely acknowledge that the responsible vessels for hemoptysis primarily originate from the systemic circulation, particularly the hypertrophy and rupture of bronchial arteries and NBSAs (11,12). In our study, all non-recurrence patients had identifiable and embolizable bronchial arteries, whereas recurrence patients more often had complex vascular supplies (multiple non-bronchial systemic arteries and pulmonary artery involvement). Therefore, the apparently “protective” effect of BA involvement in univariate analysis does not mean that BA hypertrophy prevents recurrence. Instead, it reflects that patients whose bleeding originates from easily identifiable and embolizable bronchial arteries tend to have better outcomes, while those with more complex, multi-source arterial supply are more likely to experience recurrence. This is a classic example of confounding by disease complexity. In patients with hemoptysis due to bronchiectasis and chronic pulmonary infections, NBSAs are common sources, with the internal thoracic, intercostal, and inferior phrenic arteries being the most frequent. NBSA supply has been confirmed as an independent risk factor for hemoptysis recurrence, closely related to their diverse origins and complex anatomy (13). Early recurrence after initial embolization may stem from missed vessels during the procedure. Separately, progression of the underlying pulmonary disease can contribute to recurrent bleeding by increasing pressure in the responsible vessels, promoting the formation of neo-collaterals, and causing recanalization. This study corroborates this point, with an NBSA embolization rate of 96.6% and a significantly higher median number of embolized NBSAs in the recurrence group compared to the non-recurrence group. Therefore, for hemoptysis patients with NBSA supply, especially those with chronic pulmonary infections, thorough embolization should be combined with aggressive treatment of the primary disease to reduce recurrence risk. Beyond systemic circulation sources, this study also identified an important role for the pulmonary artery system in CPA-related hemoptysis. The results showed that 39.7% of CPA patients had pulmonary artery involvement, with the proportion being significantly higher in the recurrence group. These patients also had a significantly shorter hemoptysis-free survival period. This indicates that the pulmonary artery system, particularly PAP, constitutes a critical source of bleeding contributing to BAE failure and long-term hemoptysis recurrence. Pathogenetically, the formation of PAP results from persistent erosion of the vessel wall by Aspergillus-related inflammation, compounded by the continuous hemodynamic stress from pulmonary artery flow. This leads to focal weakening and outward bulging of the vessel wall, eventually forming a pseudoaneurysm encapsulated only by the adventitia or surrounding organized tissue (14). The emergence of such lesions signifies an escalation of bleeding risk from simple mucosal capillary oozing to potentially fatal massive hemoptysis originating from major vascular structures. It also suggests this area as the core region of highest disease activity and most severe tissue destruction. Notably, Shin et al. proposed that in cases of severe systemic-to-pulmonary shunts, PAP might be clearly visualized on systemic angiography due to retrograde filling of contrast but remain occult on pulmonary angiography (15). Therefore, a dual systemic-pulmonary circulation assessment is essential for CPA patients with hemoptysis. Several limitations of this study must be acknowledged. it inevitably suffers from selection bias and missing information. Future validation with larger-scale, multicenter prospective cohort studies is required. Second, the lack of detailed data on post-discharge medications and treatment strategies, coupled with potentially ambiguous patient descriptions, may introduce significant bias. Finally, the study focused solely on hemoptysis patients requiring interventional therapy and may not be representative of the entire CPA population. Conclusions This study demonstrates that pulmonary artery involvement is an independent risk factor for hemoptysis recurrence after BAE in patients with CPA. Traditional embolization strategies for hemoptysis have predominantly focused on the systemic circulation. However, CPA patients frequently present with concurrent pulmonary artery aneurysms or pseudoaneurysms, which are prone to cause re-bleeding after BAE. Therefore, in the clinical management of CPA-related hemoptysis, a “dual systemic-pulmonary circulation assessment” strategy should be adopted. While embolizing systemic responsible vessels, proactive identification and management of pulmonary artery lesions are crucial to improve long-term outcomes and reduce the rate of hemoptysis recurrence. Supplementary The article’s supplementary files as Acknowledgments The authors thank all the patients who participated in this study. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was approved by the Ethics Committee of The Affiliated Hospital of Jianghan University (approval No. WHSHIRB-G-2024002). All participants provided the written informed consents prior to study. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1-2725/rc Funding: This work was supported by Wuhan Natural Science Fund Exploration Program (Chenguang Program) (grant No. 2025040601020211) and Hubei Provincial Natural Science Foundation (grant No. 2025AFC049). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1-2725/coif). The authors have no conflicts of interest to declare. Data Sharing Statement Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1-2725/dss References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1-2725/prf Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1-2725/dss